Tag Archives: Merck

Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb's kidney cancer share

Bristol-Myers Squibb investors have been dreading positive kidney cancer results from archrival Merck for months. And now that they’re here, they might do even more damage to Bristol-Myers’ market share than some industry watchers expected. Results released late Monday in an abstract show that Merck’s immuno-oncology star Keytruda, in tandem with Pfizer’s Inlya, slashed the risk… Read More »

Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure

Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More »

Merck's Keytruda puts heat on Pfizer, Merck KGaA's Bavencio with new Merkel cell OK

Merck’s latest Keytruda approval isn’t necessarily a huge one for the New Jersey drugmaker when it comes to sales. But it’s a big deal for Pfizer and Merck KGaA, maker of rival drug Bavencio. Wednesday, the FDA green-lighted Merck’s immuno-oncology blockbuster in rare skin cancer Merkel cell carcinoma, an area where Bavencio had previously held… Read More »